Seegene Technologies, Inc. Logo
2016-03-08 14:35
Seegene Technologies to Unleash Customized Multiplex PCR Solutions and Support for U.S. Market
SAN FRANCISCO--(Business Wire/Korea Newswire) March 8, 2016 -- Seegene Technologies, Inc., a wholly-owned subsidiary of Seegene, Inc. (096530. KQ) (, a global developer of multiplex molecular technologies and multiplex clinical molecular diagnostics (M-MoDx), is making Seegene’s proprietary multiplex PCR assay technology available for innovative research applications in the U.S. Seegene Technologies will be responsible for leading the U.S. strategy as the company evaluates opportunities for its existing portfolio of CE-marked in vitro diagnostics (IVD) products in the market.

The company made the announcement today at the 2016 Molecular Medicine Tri-Conference (Tri-Con) in San Francisco. This marks the official launch of its U.S. custom services and innovation division to better serve its customers and partnerships for molecular diagnostic development, clinical and translational research, and other life science and agricultural applications. With company headquarters in Seoul, South Korea, this new division will serve as the technology innovation arm of the parent corporation. The U.S. offices are located in Concord, California.

In addition, Seegene plans future submissions to the U.S. Food & Drug Administration (FDA) of multiplex tests in the areas of infectious disease, such as respiratory disease, gastrointestinal infections and women’s health. In February 2015, Seegene obtained its first 510(k) market clearance for its TOCE™-based herpes simplex virus (HSV) types 1 and 2 assay. Seegene has announced other strategic partnerships with global diagnostic companies and will continue to seek and support global diagnostic partnerships for molecular and companion diagnostic development.

According to Dr. Jong-Yoon Chun, CEO and Founder of Seegene, “Our success at providing complex, yet cost-effective, multiplex PCR molecular diagnostic assays throughout Europe, Asia, Canada, Middle East and Latin America provides us with a solid foundation from which to build on to serve the U.S. market as well.”

Seegene’s technology and clinical utility will be demonstrated during two speaker presentations during Tri-Con, both of which are open to the press:

· “‘Fit-for-Workflow’ considerations for designing multiplex PCR assays for SNP detection and target enrichment,” led by Young Kim, Ph.D., Lead Application Scientist, Seegene is scheduled on Tuesday, March 8 at 3:40 p.m. PST. Conventional approaches to assay development using PCR are generally limited to very few targets, which is not an ideal companion to NGS. Using examples from BCR-ABL, thrombosis, HPV genotyping, and others, we will discuss novel approaches to develop high-multiplex RT-PCR and qPCR assays that achieve high-throughput, target complexity, specificity and sensitivity.

· “Molecular Diagnostics for Infectious Disease - Advancing Microbial Diagnostics to Improve Detection and Patient Outcome,” led by Diane Hirigoyen, M.S., Lead Molecular Specialist, University of Minnesota, Hennepin County Medical Center (HCMC), will be a lunch symposium beginning at 12:40 p.m. PST on Wednesday, March 9, 2016. The session will include a discussion about the increase in the incidence of active TB among certain U.S. populations, resulting in increased detection of multi-drug resistant (MDR) and extreme resistant (XDR) strains of TB as a result. The session will share the experience of The Mycobacteriology Laboratory at HCMC and results on the emergence of TB and TB-like diseases in an inner city and active immigrant community.

Seegene will exhibit in Booth 223 at Tri-Con in San Francisco from March 7-9, 2016. For more information, visit

About Seegene

Seegene is the world’s leading developer of multiplex molecular technologies and multiplex clinical molecular diagnostics (M-MoDx). Seegene’s core enabling technologies DPO™, TOCE™, and MuDT™, are the foundation for M-MoDx tests that can simultaneously detect multiple targets with high sensitivity, specificity and reproducibility. Seegene’s products detect multi-pathogens with great reliability and throughput, ultimately providing the most economical basis for saving time, labor and cost. Seegene’s mission is to maintain leadership in molecular diagnostics for infectious diseases, genetics, pharmacogenetics, and oncology using innovative proprietary technologies.

View source version on
Seegene Technologies, Inc. 전체 보도자료 보기
이 뉴스는 기업·기관이 발표한 보도자료 전문입니다. 언론 매체와 블로그는 보도를 목적으로 이 보도자료를 사용할 수 있습니다. 보도자료 등록 안내
Media Contact

Chempetitive Group for Seegene
Andrea Vuturo

이 보도자료 관련 분야

건강  의료기기  설립  해외

관심 분야 보도자료 구독 방법

가입하면 관심 분야 보도자료를 마이 뉴스와 이메일로 볼 수 있습니다. 스마트폰과 RSS로도 가능합니다.

보도자료 배포 서비스 안내

뉴스와이어는 4천여개 언론매체에서 일하는 1만7천여명의 기자에 보도자료를 배포해 언론이 보도할 수 있게 합니다.

해외 보도자료 배포 안내
비즈니스와이어와 제휴해 해외 언론에 보도자료를 배포합니다.